Generic Drug Approvals In US Off To Slow Start In FY 2020
Executive Summary
US FDA reports another low tally of full approvals in October, but stakeholders are not worried given the agency's history of record-breaking totals year over year.
You may also be interested in...
December ANDA Rush Is Largest In Two Years
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
December ANDA Rush Is Largest Monthly Haul In Two Years
However, the month may be losing its influence over the US FDA's annual submission total.
ANDA Approval Records Likely To End
CDER director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.